Fardis Maria 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Dec 4, 2019
Insider Transaction Report
Form 4
Fardis Maria
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2019-11-01$21.97/sh−1,894$41,611→ 310,147 total - Tax Payment
Common Stock
2019-12-02$22.66/sh−1,894$42,918→ 308,253 total
Footnotes (2)
- [F1]Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.
- [F2]Shares reported include unvested Restricted Stock Units ("RSUs").